Clean Cells acquires Anaquant to expand biopharma quality control with mass spectrometry expertise
French biopharma quality control services provider Clean Cells today announces its acquisition of French company Anaquant, a specialist in mass-spectrometry-based bioanalysis. By acquiring Anaquant, Clean Cells expands its analytical platform to support biopharma companies from early-stage development through regulatory-ready GMP testing. Acquisition Clean Cells acquires Anaquant to expand biopharma quality control with mass spectrometry expertise By acquiring Anaquant, Clean Cells expands its analytical platform to support biopharma companies from early-stage development through regulatory-ready GMP testing.
Key Takeaways
- Cate Lawrence 5 hours ago Share Share Send email Copy link French biopharma quality control services provider Clean Cells today announces its acquisition of French company Anaquant , a specialist in mass-spectrometry-based bioanalysis.
- "Anaquant is highly complementary to Clean Cells, bringing unique expertise that addresses a growing need in biopharmaceutical development.
Protein characterization is a critical but often underestimated layer of biopharmaceutical quality control," said Laurent Claisse, CEO of Clean Cells.
- " Under the deal, Clean Cells also obtains Anaquant's ReadyBeadsâ„¢ technology (patented 2017).
This is a proprietary reference standard product line for Host Cell Protein (HCP) profiling and targeted quantification of drug product-specific HCPs.
- The acquisition creates an end-to-end analytical offering for Clean Cells, spanning from early-stage method development through to GMP-grade release testing.
"Anaquant was built on the idea that mass spectrometry-based protein characterization should be as accessible and as reliable as any other standard quality control method in biopharmaceutical development.
- Financial terms were not disclosed.
By acquiring Anaquant, Clean Cells expands its analytical platform to support biopharma companies from early-stage development through regulatory-ready GMP testing. Acquisition Clean Cells acquires Anaquant to expand biopharma quality control with mass spectrometry expertise By acquiring Anaquant, Clean Cells expands its analytical platform to support biopharma companies from early-stage development through regulatory-ready GMP testing. Cate Lawrence 5 hours ago Share Share Send email Copy link French biopharma quality control services provider Clean Cells today announces its acquisition of French company Anaquant , a specialist in mass-spectrometry-based bioanalysis.
Founded in 2020, Clean Cells, a subsidiary of Clean Biologics, offers: Quality control and biological safety tests for biopharmaceutical products to assist in regulatory compliance, Production of cell banks and GMP-grade BSL2/BSL3 virus seed stock, Supply of secure storage for these products, alongside development and validation of bespoke analysis tools. Anaquant is a private Contract Research Organization (CRO) specialized in protein quantification and identification by Mass Spectrometry (MS) for better drug development. As part of the acquisition, Clean Cells takes entire ownership of Anaquant's brand, intellectual property, proprietary mass spectrometry-based analytics platform, equipment and existing client relationships, strengthening Clean Cells' capabilities in protein characterization, a critical requirement in biopharmaceutical quality control and regulatory readiness.
"Anaquant is highly complementary to Clean Cells, bringing unique expertise that addresses a growing need in biopharmaceutical development. Protein characterization is a critical but often underestimated layer of biopharmaceutical quality control," said Laurent Claisse, CEO of Clean Cells. "Anaquant has developed standardised mass spectrometry methods that are accessible to early-phase developers and generate valuable data from the earliest stages, laying the foundation for future regulatory submissions.
For more details please read the original article at Tech.eu.
Continue Learning
Comments
Sign in to join the conversation